Koru Medical Systems (Nasdaq:KRMD) announced that it entered into a development agreement with a manufacturer of subcutaneous immunoglobulin therapy (SCIg).
The agreement aims to develop and seek regulatory approval for the Freedom Infusion System with an SCIg prefilled syringe.
Koru said the agreement provides it the opportunity to develop an adaptation to the Freedom system. This adaptation enables the use of an SCIg prefilled syringe by patients globally. The company plans to seek regulatory authorization for this new adaptation.
“As Koru Medical looks to simplify subcutaneous drug delivery for patients in the home, we are excited to partner with another major pharmaceutical company to further innovate our Freedom Infusion System for use with their prefilled syringes,” said Linda Tharby, Koru president and CEO. “Patients prefer prefilled syringes as they simplify the challenging task of transferring medication from vials. The Freedom Infusion System is the only infusion system approved for prefilled syringes, and we are excited by the opportunity to expand the number of prefilled subcutaneous therapies that are FDA approved for our innovative infusion system.”
Koru declined to disclose the terms of the deal.
The company develops, manufactures and commercializes subcutaneous drug delivery systems. Its Freedom platform currently includes the Freedom60 and FreedomEdge syringe infusion drivers, Precision Flow Rate Tubing and HIgH-Flo Subcutaneous Safety Needle Sets.
Uses for Koru’s devices include at-home infusions and alternate care settings.
